Combination Therapy for Solid Tumors: Taking a Classic CAR on New Adventures
- PMID: 33064993
- DOI: 10.1016/j.ccell.2020.10.003
Combination Therapy for Solid Tumors: Taking a Classic CAR on New Adventures
Abstract
CD19-specific CAR-T cell therapies are the gold standard of adoptive cellular immunotherapy for hematopoietic malignancies. In Science Translational Medicine, Park et al. develop an oncolytic vaccinia virus that introduces truncated CD19 expression in solid tumors, which are then eradicated by CD19-specific CAR-T cells in immunodeficient and immunocompetent mouse models.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of Interests A.D.P. and T.R.K. are inventors on patent applications filed by the University of Pennsylvania related to CAR-T cells. A.D.P. has licensed intellectual property to Novartis and Tmunity Therapeutics. A.D.P. is founder of Cartio Therapeutics and an advisor for GO Therapeutics.
Comment on
-
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.Sci Transl Med. 2020 Sep 2;12(559):eaaz1863. doi: 10.1126/scitranslmed.aaz1863. Sci Transl Med. 2020. PMID: 32878978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical